Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study
Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study
S. Pillai, Sonia Montmayeur, Maria Lucia Buziqui Piruzeli, Raj Chovatiya et al.
Journal
Dermatology and Therapy
Topics
Dermatology and Skin Diseases
article
Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study
S. Pillai, Sonia Montmayeur, Maria Lucia Buziqui Piruzeli, Raj Chovatiya, L. Stein Gold, Christopher F. Schuster, M. Silk, Lindsay Ackerman, Amber Reck Atwater, B. Lockshin, Waibel Js, Evangeline Pierce, Jamie Weisman, Jinglin Zhong, Jennifer Proper, Gil Yosipovitch, María José Rueda, Andrew Blauvelt, Jerry Bagel, Eric Simpson, Jenny E. Murase, David Rosmarin, Jonathan I. Silverberg, Matthew Zirwas
article en
Abstract
No abstract available for this paper.
Publication Tag
Dermatology and TherapyVol. 16(2)
Institutions
University of Miami (US), Oregon Health & Science University (US), Eli Lilly (United States) (US), University of California, San Francisco (US), Rosalind Franklin University of Medicine and Science (US), George Washington University (US), Bexley Hall (US), Henry Ford Hospital (US), Partners In Care (US), Maryland Department of Natural Resources (US), Ohio University (US), IQVIA (United States) (US), Miami Dermatology and Laser Institute (US), Probity Medical Research (CA), Palo Alto Institute (US), Windsor Dermatology (US), Dermatology Specialists (US), Indiana University School of Medicine, Indiana University – Purdue University Indianapolis (US)